Dream – Santiveri | 20 Capsules
9,00 €
Dream – Santiveri | 20 Capsules is a food supplement based on melatonin and titrated extracts of griffonia, California poppy, passionflower and valerian. Melatonin helps reduce the time needed to fall asleep California poppy, passionflower and valerian c
0 units available!
Description
Dream – Santiveri
Presentation: 9 g case. 20 capsules
Food supplement based on melatonin and titrated extracts of griffonia, California poppy, passionflower and valerian
With melatonin, griffonia, California poppy, passionflower and valerian. Based on titrated dry extracts.
Ingredients: dry extract of griffonia (Griffonia simplicifolia (DC) Baill. – seeds) titrated to 30% in 5-HTP (5-hydroxytryptophan), capsule of plant origin (hydroxypropylmethylcellulose: coating agent), dry extract of California poppy ( Eschscholzia californica Cham. – aerial part) titrated to 0.35% in protopin, dry extract of valerian (Valeriana officinalis L. – root) titrated to 0.8% of sesquiterpenic acids expressed as valerenic acid, dry extract of passionflower (Passiflora incarnata L. – aerial part) titrated to 4% in vitexin, anti-caking agents (silicon dioxide and magnesium stearate), melatonin.
Instructions for use: Take 1 capsule one hour before bedtime. The effect of melatonin on reducing the time needed to fall asleep is achieved by taking 1 mg of melatonin shortly before going to sleep.
1 capsule provides: 1 mg of melatonin, 150 mg of griffonia dry extract (5-Hydroxytryptophan: 45 mg), 100 mg of California poppy dry extract (protopin: 0.35 mg), 50 mg of valerian dry extract (valerenic acid: 0.4 mg), 50 mg of dry passionflower extract (vitexin: 2 mg).
- Store in a cool, dry place, protected from light.
- Do not exceed the recommended daily dose.
- Food supplements should not be used as substitutes for a varied and balanced diet.
- Keep out of the reach of children.
- It should not be consumed by pregnant or breastfeeding women, nor by those who are being treated with antidepressants or who suffer from kidney failure.
No Comments